Drugs / BMT101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03133130 | Jul 2017 → Feb 2018 | reactive cutaneous fibrous lesion | Hugel | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04012099 | Aug 2019 → May 2023 | reactive cutaneous fibrous lesion | Hugel | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-01-25 | Olix Pharmaceuticals, Inc. | Regulatory 올릭스, RNA 간섭 치료제 임상개시 승인 olixpharma.com ↗
OLX101(BMT101·비대흉터치료제)'이 지난 23일 식품의약품안전처로부터 임상시험계획(IND·Investigational New Drug) 승인을 받았다고 25일 밝혔다. |
| 2014-12-11 | Olix Pharmaceuticals, Inc. | Regulatory 올릭스, 흉터치료제 ‘범부처전주기신약개발사업’ 선정 olixpharma.com ↗
올릭스 주식회사(대표 홍선우, 구 BMT(주))는 5일 (재)범부처신약개발사업단과 자가전달 RNA 간섭기술을 이용한 흉터억제 신약 BMT101 개발 과제에 대한 협약을 체결했다고 밝혔다. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-01-25 | Olix Pharmaceuticals, Inc. | 올릭스, RNA 간섭 치료제 임상개시 승인 olixpharma.com ↗ |
| 2014-12-11 | Olix Pharmaceuticals, Inc. | 올릭스, 흉터치료제 ‘범부처전주기신약개발사업’ 선정 olixpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04012099 ↗ |
| Modality | Small interfering RNA (siRNA) | “siRNA” NCT03133130 ↗ |
| Route | Other | “Intradermal Dosage Form” NCT03133130 ↗ |